Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line

Naofumi Seira, Naoki Yanagisawa, Akiko Suganami, Takuya Honda, Makiko Wasai, John W. Regan, Keijo Fukushima, Naoto Yamaguchi, Yutaka Tamura, Takayoshi Arai, Toshihiko Murayama, Hiromichi Fujino

Research output: Research - peer-reviewArticle

Abstract

Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.

LanguageEnglish (US)
Pages1806-1812
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number10
StatePublished - 2017

Fingerprint

15-hydroxyprostaglandin dehydrogenase
Colonic Neoplasms
Cell Line
Growth
Neoplasms
indole
Prostaglandins E
Cell Cycle
PPAR gamma
S Phase

Keywords

  • 15-hydroxyprostaglandin dehydrogenase
  • Colon cancer
  • Indole compound
  • MW-03
  • Peroxisome proliferator-activated receptor-γ
  • Prostaglandin E2

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line. / Seira, Naofumi; Yanagisawa, Naoki; Suganami, Akiko; Honda, Takuya; Wasai, Makiko; Regan, John W.; Fukushima, Keijo; Yamaguchi, Naoto; Tamura, Yutaka; Arai, Takayoshi; Murayama, Toshihiko; Fujino, Hiromichi.

In: Biological and Pharmaceutical Bulletin, Vol. 40, No. 10, 2017, p. 1806-1812.

Research output: Research - peer-reviewArticle

Seira, N, Yanagisawa, N, Suganami, A, Honda, T, Wasai, M, Regan, JW, Fukushima, K, Yamaguchi, N, Tamura, Y, Arai, T, Murayama, T & Fujino, H 2017, 'Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line' Biological and Pharmaceutical Bulletin, vol 40, no. 10, pp. 1806-1812.
Seira, Naofumi ; Yanagisawa, Naoki ; Suganami, Akiko ; Honda, Takuya ; Wasai, Makiko ; Regan, John W. ; Fukushima, Keijo ; Yamaguchi, Naoto ; Tamura, Yutaka ; Arai, Takayoshi ; Murayama, Toshihiko ; Fujino, Hiromichi. / Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line. In: Biological and Pharmaceutical Bulletin. 2017 ; Vol. 40, No. 10. pp. 1806-1812
@article{5d2fb02746ae4b13b4681a741185d746,
title = "Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line",
abstract = "Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.",
keywords = "15-hydroxyprostaglandin dehydrogenase, Colon cancer, Indole compound, MW-03, Peroxisome proliferator-activated receptor-γ, Prostaglandin E2",
author = "Naofumi Seira and Naoki Yanagisawa and Akiko Suganami and Takuya Honda and Makiko Wasai and Regan, {John W.} and Keijo Fukushima and Naoto Yamaguchi and Yutaka Tamura and Takayoshi Arai and Toshihiko Murayama and Hiromichi Fujino",
year = "2017",
volume = "40",
pages = "1806--1812",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line

AU - Seira,Naofumi

AU - Yanagisawa,Naoki

AU - Suganami,Akiko

AU - Honda,Takuya

AU - Wasai,Makiko

AU - Regan,John W.

AU - Fukushima,Keijo

AU - Yamaguchi,Naoto

AU - Tamura,Yutaka

AU - Arai,Takayoshi

AU - Murayama,Toshihiko

AU - Fujino,Hiromichi

PY - 2017

Y1 - 2017

N2 - Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.

AB - Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.

KW - 15-hydroxyprostaglandin dehydrogenase

KW - Colon cancer

KW - Indole compound

KW - MW-03

KW - Peroxisome proliferator-activated receptor-γ

KW - Prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=85030767955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030767955&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 1806

EP - 1812

JO - Biological and Pharmaceutical Bulletin

T2 - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -